Benzinga | Apr 28, 2021 10:39AM EDT

Black Diamond Therapeutics To Present Phase 1 BDTX-189 Data In Advanced Solid Tumors At American Society of Clinical Oncology

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that initial PK, safety, and preliminary efficacy data from the Phase 1 dose-escalation portion of the MasterKey-01 trial of BDTX-189 in patients with advanced solid tumors will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021.



Presentation details are as follows:

Title: Safety and Preliminary Efficacy from the Phase 1 Portion of MasterKey-01: A First-in-Human Dose-Escalation Study to Determine the Recommended Phase 2 Dose (RP2D), Pharmacokinetics (PK), and Preliminary Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB mutations, in Patients with Advanced Solid Malignancies

Session Type: Poster Session

Session: Developmental Therapeutics -- Molecularly Targeted Agents and Tumor Biology

Date and Time: Friday, June 4, 9:00 AM ET

Abstract ID: 3086

Title: Clinical pharmacokinetics of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study

Session Type: Poster Session

Session: Developmental Therapeutics -- Molecularly Targeted Agents and Tumor Biology

Date and Time: Friday, June 4, 9:00 AM ET

Abstract ID: 3097

Full abstracts will be published online at 5:00 PM ET on May 19, 2021 on the ASCO website at www.asco.org.